Clinical markers of immunotherapy outcomes in advanced sarcoma

BACKGROUND: Despite immunotherapy’s promise in oncology, its use for sarcoma remains challenging. There are no sarcoma-specific biomarkers for immune checkpoint inhibitors (ICI). Previously, we reported our institutional experience highlighting ICI activity in 29 patients with sarcoma. In this study...

Descripción completa

Detalles Bibliográficos
Autores principales: Husain, Marium, Quiroga, Dionisia, Kim, Han Gil, Lenobel, Scott, Xu, Menglin, Iwenofu, Hans, Chen, James L., Verschraegen, Claire, Liebner, David, Tinoco, Gabriel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10080913/
https://www.ncbi.nlm.nih.gov/pubmed/37029351
http://dx.doi.org/10.1186/s12885-023-10758-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10080913/
https://www.ncbi.nlm.nih.gov/pubmed/37029351
http://dx.doi.org/10.1186/s12885-023-10758-w

Ejemplares similares